Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
All content for Healthcare Unfiltered is the property of Chadi Nabhan and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
Returning guest Anthony DiGiorgio, DO, a practicing neurosurgeon at UCSF and noted health policy commentator, takes a deep dive into the 340B Drug Pricing Program—one of the most consequential yet misunderstood mechanisms in US healthcare. He traces the program’s origins in the early 1990s, designed to help safety net hospitals stretch scarce federal resources to better serve vulnerable patients. Dr. DiGiorgio examines how, over time, many institutions have leveraged 340B as an ancillary reve...
Healthcare Unfiltered
Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
